Dianthus Therapeutics (NASDAQ:DNTH) Shares Down 3.3% – Time to Sell?

Dianthus Therapeutics, Inc. (NASDAQ:DNTH)’s share price dropped 3.3% during trading on Friday . The company traded as low as $39.10 and last traded at $39.8690. Approximately 66,377 shares traded hands during mid-day trading, a decline of 89% from the average daily volume of 618,032 shares. The stock had previously closed at $41.21.

Wall Street Analyst Weigh In

Several equities analysts have recently commented on DNTH shares. Robert W. Baird increased their target price on Dianthus Therapeutics from $50.00 to $67.00 and gave the company an “outperform” rating in a research note on Tuesday, September 9th. Stifel Nicolaus upped their price target on Dianthus Therapeutics from $52.00 to $65.00 and gave the company a “buy” rating in a research note on Friday, September 12th. Guggenheim increased their price target on shares of Dianthus Therapeutics from $92.00 to $100.00 and gave the company a “buy” rating in a research note on Tuesday, September 9th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Dianthus Therapeutics in a report on Wednesday, October 8th. Finally, HC Wainwright increased their price target on Dianthus Therapeutics from $40.00 to $47.00 and gave the stock a “buy” rating in a report on Monday, November 10th. Eight research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company. Based on data from MarketBeat, Dianthus Therapeutics currently has an average rating of “Moderate Buy” and an average target price of $63.43.

Dianthus Therapeutics Stock Performance

The firm has a market capitalization of $1.69 billion, a price-to-earnings ratio of -11.26 and a beta of 1.55. The firm’s 50 day simple moving average is $40.20 and its 200 day simple moving average is $31.14.

Dianthus Therapeutics (NASDAQ:DNTH) last posted its quarterly earnings data on Wednesday, November 5th. The company reported ($0.97) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.86) by ($0.11). The company had revenue of $0.40 million for the quarter, compared to analysts’ expectations of $0.58 million. Dianthus Therapeutics had a negative return on equity of 33.02% and a negative net margin of 4,106.04%. As a group, sell-side analysts forecast that Dianthus Therapeutics, Inc. will post -2.61 earnings per share for the current year.

Insider Activity at Dianthus Therapeutics

In other Dianthus Therapeutics news, CFO Ryan Savitz sold 20,000 shares of the firm’s stock in a transaction that occurred on Thursday, December 4th. The shares were sold at an average price of $45.18, for a total value of $903,600.00. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, EVP Simrat Randhawa sold 109,031 shares of the firm’s stock in a transaction on Friday, November 14th. The stock was sold at an average price of $38.14, for a total value of $4,158,442.34. Following the completion of the sale, the executive vice president directly owned 4,000 shares of the company’s stock, valued at approximately $152,560. This trade represents a 96.46% decrease in their position. The disclosure for this sale is available in the SEC filing. Over the last quarter, insiders have sold 216,538 shares of company stock valued at $8,283,175. Company insiders own 8.15% of the company’s stock.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the company. Wellington Management Group LLP grew its position in Dianthus Therapeutics by 3,366.9% during the 3rd quarter. Wellington Management Group LLP now owns 2,577,662 shares of the company’s stock worth $101,431,000 after acquiring an additional 2,503,311 shares during the last quarter. Vestal Point Capital LP increased its holdings in Dianthus Therapeutics by 88.2% in the 2nd quarter. Vestal Point Capital LP now owns 3,200,000 shares of the company’s stock worth $59,616,000 after acquiring an additional 1,499,931 shares during the last quarter. Braidwell LP bought a new position in shares of Dianthus Therapeutics in the third quarter valued at approximately $32,859,000. Polar Capital Holdings Plc bought a new stake in Dianthus Therapeutics during the third quarter valued at approximately $29,434,000. Finally, Fairmount Funds Management LLC increased its holdings in Dianthus Therapeutics by 22.2% during the 3rd quarter. Fairmount Funds Management LLC now owns 3,307,191 shares of the company’s stock valued at $130,138,000 after purchasing an additional 600,000 shares during the period. 47.53% of the stock is owned by institutional investors and hedge funds.

Dianthus Therapeutics Company Profile

Dianthus Therapeutics, Inc, a clinical-stage biotechnology company, develops complement therapeutics for patients with severe autoimmune and inflammatory diseases. It is developing DNTH103, a monoclonal antibody, which is in Phase 2 clinical trial, for the treatment of generalized myasthenia gravis, multifocal motor neuropathy, and chronic inflammatory demyelinating polyneuropathy. Dianthus Therapeutics, Inc was founded in 2019 and is headquartered in New York, New York.